Weiguang Biotech announced that from January 1 to June 30, 2026, net profit attributable to shareholders of listed companies was 43.86 million yuan - 53.82 million yuan, a year-on-year decrease of 50%-60%; net profit after deduction was 42.52 million yuan to 53.15 million yuan, a year-on-year decrease of 50%-60%; and basic earnings per share was 0.1,898 yuan/share - 0.2373 yuan/share. The decline in performance was mainly due to tax policy adjustments, changes in tax calculation methods for the blood products business, and increased market competition, which led to a decline in blood product sales.

Weiguang Biotech announced that from January 1 to June 30, 2026, net profit attributable to shareholders of listed companies was 43.86 million yuan - 53.82 million yuan, a year-on-year decrease of 50%-60%; net profit after deduction was 42.52 million yuan to 53.15 million yuan, a year-on-year decrease of 50%-60%; and basic earnings per share was 0.1,898 yuan/share - 0.2373 yuan/share. The decline in performance was mainly due to tax policy adjustments, changes in tax calculation methods for the blood products business, and increased market competition, which led to a decline in blood product sales.